Asset Details
Do you wish to reserve the book?
Memantine in Moderate-to-Severe Alzheimer's Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Memantine in Moderate-to-Severe Alzheimer's Disease
Do you wish to request the book?
Memantine in Moderate-to-Severe Alzheimer's Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Memantine in Moderate-to-Severe Alzheimer's Disease
2003
Overview
Overstimulation of the
N
-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. This 28-week study compared memantine, an NMDA-receptor antagonist, with placebo in persons with moderate-to-severe Alzheimer's disease. Among the patients who completed the study, memantine appeared to confer benefit in terms of activities of daily living and other measures; analysis of the last observation carried forward for the whole group supported this conclusion.
Antiglutamatergic therapy may help in moderate-to-severe disease.
Alzheimer's disease affects at least 15 million persons throughout the world.
1
,
2
The number of persons with Alzheimer's disease is increasing substantially as populations age.
3
As Alzheimer's disease advances, patients become progressively impaired in both cognitive and functional capacities,
2
,
4
and the burden on caregivers increases. Pharmacologic treatments are currently approved for treating mild-to-moderate Alzheimer's disease.
5
However, there are no treatments for the more advanced stages of Alzheimer's disease.
Glutamate is the principal excitatory neurotransmitter in the brain.
6
,
7
Glutamatergic overstimulation may result in neuronal damage, a phenomenon that has been termed excitotoxicity. Such excitotoxicity ultimately leads to neuronal calcium . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Alzheimer Disease - classification
/ Alzheimer Disease - drug therapy
/ Alzheimer Disease - psychology
/ Anticonvulsants. Antiepileptics. Antiparkinson agents
/ Behavior
/ Biological and medical sciences
/ Excitatory Amino Acid Antagonists - adverse effects
/ Excitatory Amino Acid Antagonists - therapeutic use
/ Female
/ Humans
/ Male
/ N-Methylaspartate - antagonists & inhibitors
